Nothing Special   »   [go: up one dir, main page]

MA49981A - Procédés et compositions de préparation de cellules génétiquement modifiées - Google Patents

Procédés et compositions de préparation de cellules génétiquement modifiées

Info

Publication number
MA49981A
MA49981A MA049981A MA49981A MA49981A MA 49981 A MA49981 A MA 49981A MA 049981 A MA049981 A MA 049981A MA 49981 A MA49981 A MA 49981A MA 49981 A MA49981 A MA 49981A
Authority
MA
Morocco
Prior art keywords
compositions
processes
preparation
genetically modified
modified cells
Prior art date
Application number
MA049981A
Other languages
English (en)
Inventor
Mark L Bonyhadi
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of MA49981A publication Critical patent/MA49981A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
MA049981A 2017-08-09 2018-08-09 Procédés et compositions de préparation de cellules génétiquement modifiées MA49981A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762543359P 2017-08-09 2017-08-09

Publications (1)

Publication Number Publication Date
MA49981A true MA49981A (fr) 2020-06-17

Family

ID=63405422

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049981A MA49981A (fr) 2017-08-09 2018-08-09 Procédés et compositions de préparation de cellules génétiquement modifiées

Country Status (12)

Country Link
US (2) US20200239910A1 (fr)
EP (1) EP3664835B1 (fr)
JP (2) JP2020530294A (fr)
KR (1) KR20200046045A (fr)
CN (1) CN111263641A (fr)
AU (1) AU2018313952A1 (fr)
BR (1) BR112020001601A2 (fr)
CA (1) CA3070575A1 (fr)
MA (1) MA49981A (fr)
MX (1) MX2020001491A (fr)
NZ (1) NZ761124A (fr)
WO (1) WO2019032929A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3064205A1 (fr) 2017-05-26 2018-11-29 Abvitro Llc Sequencage de bibliotheque de polynucleotides a haut rendement et analyse de transcriptome
MX2019014268A (es) 2017-06-02 2020-08-03 Juno Therapeutics Inc Artículos de manufactura y métodos para tratamiento usando terapia celular adoptiva.
KR20200054178A (ko) 2017-08-09 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법
SG11202101204TA (en) * 2018-08-09 2021-03-30 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
CA3142108A1 (fr) 2019-05-28 2020-12-03 Miltenyi Biotec B.V. & Co. KG Procede de production de lymphocytes t genetiquement modifies
US20220412954A1 (en) 2019-11-05 2022-12-29 Juno Therapeutics, Inc. Methods of determining attributes of therapeutic t cell compositions
WO2021231657A1 (fr) 2020-05-13 2021-11-18 Juno Therapeutics, Inc. Procédés d'identification de caractéristiques associées à une réponse clinique et leurs utilisations
KR102594083B1 (ko) 2020-07-07 2023-10-25 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
WO2023230548A1 (fr) 2022-05-25 2023-11-30 Celgene Corporation Procédé de prédiction d'une réponse à une thérapie par lymphocyte t

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1990007380A2 (fr) 1988-12-28 1990-07-12 Stefan Miltenyi Procedes et matieres pour la separation magnetique a gradient eleve de matieres biologiques
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (fr) 1994-10-26 1996-05-09 Procept, Inc. Recepteurs de lymphocites t monocatenaires solubles
WO1996018105A1 (fr) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Recepteur de lymphocyte t monocatenaire
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (fr) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Produits de recombinaison d'anticorps diriges contre le gd2, constitues d'un fragment variable (fv) a chaine simple
AU742650B2 (en) 1997-10-02 2002-01-10 Altor Bioscience Corporation Soluble single-chain T-cell receptor proteins
EE200000697A (et) 1998-05-19 2002-06-17 Avidex Limited Lahustuv T-raku retseptor
WO2000014257A1 (fr) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CA2410510A1 (fr) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation
EP1334188B1 (fr) 2000-11-07 2006-08-30 City of Hope Cellules immunitaires specifiques a cd19 redirigees
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
WO2003070752A2 (fr) 2002-02-20 2003-08-28 Dyax Corporation Ligands de liaison au complexe mhc-peptide
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
TW200502391A (en) 2003-05-08 2005-01-16 Xcyte Therapies Inc Generation and isolation of antigen-specific t cells
AU2005247950B2 (en) 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
DK2856876T3 (en) 2007-03-30 2018-04-03 Memorial Sloan Kettering Cancer Center Constitutive expression of co-stimulatory ligands on adoptively transmitted T lymphocytes
EP3338896A1 (fr) 2007-12-07 2018-06-27 Miltenyi Biotec GmbH Systèmes et procédés de traitement d'échantillons
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
WO2011056894A2 (fr) 2009-11-03 2011-05-12 Jensen Michael C Récepteur du facteur de croissance de l'épiderme tronqué (egfrt) pour la sélection de lymphocytes t transduits
US10392726B2 (en) 2010-10-08 2019-08-27 President And Fellows Of Harvard College High-throughput immune sequencing
ES2966040T3 (es) 2010-10-08 2024-04-18 Harvard College Alto rendimiento de células individuales con código de barra
CN103492406B (zh) 2010-12-09 2022-07-26 宾夕法尼亚大学董事会 嵌合抗原受体-修饰的t细胞治疗癌症的用途
CN103502438A (zh) * 2011-03-23 2014-01-08 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
KR20140033029A (ko) 2011-04-01 2014-03-17 메모리얼 슬로안-케터링 캔서 센터 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
AU2012335073B2 (en) 2011-11-11 2017-08-17 Fred Hutchinson Cancer Center Cyclin A1-targeted T-cell immunotherapy for cancer
AU2013221672B2 (en) 2012-02-13 2017-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (fr) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation
MX361760B (es) 2012-05-03 2018-12-17 Hutchinson Fred Cancer Res Receptores de celulas t con afinidad aumentada y metodos para hacer los mismos.
MX2015002101A (es) 2012-08-20 2015-07-14 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
CN104853766A (zh) 2012-10-02 2015-08-19 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
WO2014097442A1 (fr) 2012-12-20 2014-06-26 三菱電機株式会社 Dispositif embarqué et programme
WO2014144495A1 (fr) 2013-03-15 2014-09-18 Abvitro, Inc. Attribution d'un code-barres à des cellules isolées pour la découverte d'anticorps
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
ES2759260T3 (es) * 2014-04-23 2020-05-08 Juno Therapeutics Inc Métodos para aislar, cultivar y modificar genéticametne poblaciones de células inmunes para la terapia adoptiva
CN113604491A (zh) 2014-05-02 2021-11-05 宾夕法尼亚大学董事会 嵌合自身抗体受体t细胞的组合物和方法
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
SG11201702060VA (en) 2014-09-15 2017-04-27 Abvitro Inc High-throughput nucleotide library sequencing
WO2016090329A2 (fr) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Anticorps ciblant le récepteur couplé aux protéines g et procédés d'utilisation
JP6892822B2 (ja) 2014-12-05 2021-06-23 メモリアル スローン ケタリング キャンサー センター Ｂ細胞成熟化抗原を標的化する抗体および使用の方法
WO2016090320A1 (fr) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Récepteurs antigéniques chimériques ciblant l'antigène de maturation des cellules b et leurs utilisations
SG11201704547RA (en) 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof
DK3280729T3 (da) * 2015-04-08 2022-07-25 Novartis Ag Cd20-behandlinger, cd22-behandlinger og kombinationsbehandlinger med en cd19-kimær antigenreceptor (car)-udtrykkende celle
CN107849560B (zh) 2015-04-27 2021-10-22 阿布维特罗有限责任公司 对治疗剂和疾病特异性抗原进行测序、确定、配对和验证的方法
CN108369230B (zh) 2015-09-25 2021-09-17 阿布维特罗有限责任公司 用于对天然配对t细胞受体序列进行t细胞受体靶向鉴别的高通量方法

Also Published As

Publication number Publication date
NZ761124A (en) 2024-07-05
AU2018313952A1 (en) 2020-02-13
JP2023055888A (ja) 2023-04-18
EP3664835A1 (fr) 2020-06-17
BR112020001601A2 (pt) 2020-08-11
US20200239910A1 (en) 2020-07-30
JP2020530294A (ja) 2020-10-22
RU2020109867A3 (fr) 2022-01-10
US20240368625A1 (en) 2024-11-07
MX2020001491A (es) 2020-08-06
WO2019032929A1 (fr) 2019-02-14
CN111263641A (zh) 2020-06-09
KR20200046045A (ko) 2020-05-06
RU2020109867A (ru) 2021-09-14
EP3664835B1 (fr) 2024-10-23
CA3070575A1 (fr) 2019-02-14

Similar Documents

Publication Publication Date Title
MA49981A (fr) Procédés et compositions de préparation de cellules génétiquement modifiées
IL263743A (en) Cell depletion compositions and methods
IL266398A (en) Liver organoid preparations, methods for their production and their uses
IL263744A (en) Compositions and methods for depleting cd117 plus cells
IL268058A (en) Compositions and methods for depleting CD137 plus cells
IL270714A (en) Liver organoid preparations, methods for their preparation and their uses
HK1244841A1 (zh) 用於選擇性消除所關注細胞的方法和組合物
MA49979A (fr) Procédés de production de compositions de cellules génétiquement modifiées et compositions associées
IL274154A (en) Compositions and methods for diluting CD117 plus cells
MA46959A (fr) Cellules b modifiées et compositions et méthodes associées
EP3700540A4 (fr) Compositions et procédés pour la déplétion des cellules cd117+
MA53939A (fr) Compositions hémostatiques et leurs procédés de fabrication
EP3538160A4 (fr) Procédés et compositions pour la production thérapeutique à grande échelle de cellules nk de type mémoire
SG11202102431YA (en) Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
MA53445A (fr) Procédés et compositions pour la modification de plantes
IL274839A (en) Compositions and methods for diluting CD5 plus cells
ZA201902781B (en) Compositions and methods for the treatment of xerostomia
IL278201A (en) Methods and preparations for depleting cytotoxic T cells
SG11202004192XA (en) Compositions and methods for the depletion of cd2+ cells
EP3307284A4 (fr) Compositions et procédés pour l'enrichissement de cellules
MA51307A (fr) Compositions laitières fermentées et procédés de préparation de celles-ci
MA45498A (fr) Cellules treg génétiquement modifiées
MA51162A (fr) Schémas posologiques et compositions et procédés associés
DK3280401T3 (da) Sammensætninger til behandling og/eller forebyggelse af celle- eller vævsnekrose specielt rettet mod kathepsin c og/eller cela1 og/eller cela3a og/eller strukturelt relaterede enzymer dertil
EP3687575A4 (fr) Méthodes et compositions permettant d'améliorer la survie et la fonctionnalité de lymphocytes t anti-tumoraux et anti-viraux